| Active Not Recruiting | Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Express NCT04957615 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Study of GNX102 in Patients With Advanced Solid Tumors NCT04250597 | GlycoNex, Inc. | Phase 1 |
| Active Not Recruiting | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutati NCT03218826 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors Th NCT03326258 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors NCT03366103 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver NCT03217253 | National Cancer Institute (NCI) | Phase 1 |
| Completed | IACS-010759 in Advanced Cancers NCT03291938 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278 | Rutgers, The State University of New Jersey | Phase 1 |
| Completed | Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma NCT03061188 | Northwestern University | Phase 1 |
| Completed | APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid NCT03087591 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by S NCT02503709 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic NCT02721732 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy NCT02432963 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelio NCT02535312 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lym NCT02408861 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors NCT02143401 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Canno NCT02159989 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are NCT02097225 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction NCT02070549 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus NCT01822522 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ipilimumab and Imatinib Mesylate in Advanced Cancer NCT01738139 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastati NCT01787500 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian C NCT01012817 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Remove NCT00576654 | National Cancer Institute (NCI) | Phase 1 |